



State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: February 6, 2017

TO: All Louisiana Medicaid Providers

FROM: Jen Steele, Medicaid Director

SUBJECT: Louisiana Fee-for-Service (FFS) Medicaid Pharmacy Clinical Pre-Authorization for Sacubitril/valsartan (Entresto®) and Point of Sale (POS) Edits for Perampanel (Fycompa®) and Cariprazine (Vraylar®)- Effective February 14, 2017

Effective February 14, 2017, the Louisiana Department of Health Pharmacy Program in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board has established clinical pre-authorization criteria for sacubitril/valsartan (Entresto®) and Point of Sale (POS) edits on perampanel (Fycompa®) and cariprazine (Vraylar®).

SACUBITRIL/VALSARTAN (ENTRESTO®)

Clinical Pre-authorization for sacubitril/valsartan (Entresto®)

Pharmacy claims for sacubitril/valsartan (Entresto®) will be reimbursed at POS when the prescriber has obtained an approved clinical pre-authorization. Prescribers must complete the Pharmacy Clinical Pre-Authorization Form in full and fax to 1-866-797-2329. See the Clinical Pre-Authorization Form following this document or refer to www.lamedicaid.com.

Pharmacy claims without a clinical pre-authorization for sacubitril/valsartan (Entresto®) will deny at POS with:

**NCPDP rejection code 88 (DUR Reject Error) mapped to
EOB code 066 (Clinical Pre-Authorization Required- MD Fax Form to
866-797-2329)**

Override provisions should be addressed through the Clinical Pre-Authorization process.

PERAMPANEL (FYCOMPA®)

Age Limit for perampanel (Fycompa®)

Pharmacy claims for perampanel (Fycompa®) for recipients under 12 years old will deny at POS with:

**NCPDP rejection code 60 (Product/Service Not Covered for Patient Age) mapped to
EOB code 234 (P/F Age Restriction)**

After consultation with the prescriber to verify the necessity of prescribing perampanel (Fycompa®) for a recipient under 12 years old, the pharmacist may override the age restriction denial by submitting:

NCPDP 439-E4 field (Reason for Service Code) PA (Drug-Age)
NCPDP 440-E5 field (Professional Service Code) MO (Prescriber Consulted)
NCPDP 441-E6 field (Result of Service Code) 1G (Filled with Prescriber Approval)

CARIPRAZINE (VRAYLAR®)

Dose Limit for cariprazine (Vraylar®)

Recipients 15 years old or less

All pharmacy claims for any strength of cariprazine (Vraylar®) for recipients 15 years old or less will deny at POS with:

**NCPDP rejection code 88 (DUR Reject Error) mapped to
EOB code 325 (Exceeds maximum daily dose-MD Fax Override Form
to 866-797-2329)**

Overrides will be addressed using the attached Request for Prescription Override Form (Rx PA16) and through contact with staff at the Prior Authorization Unit at the University of Louisiana at Monroe (ULM).

Recipients 16 – 17 years old

Pharmacy claims for cariprazine (Vraylar®) for recipients 16 – 17 years old and a dose greater than 4.5mg/day will deny at POS:

**NCPDP rejection code 88 (DUR Reject Error) mapped to
EOB code 325 (Exceeds maximum daily dose-MD Fax Override Form
to 866-797-2329)**

Overrides will be addressed using the attached Request for Prescription Override Form (Rx PA16) and through contact with staff at the Prior Authorization Unit at the University of Louisiana at Monroe (ULM).

Recipients 18 years old or older

Pharmacy claims for cariprazine (Vraylar®) for recipients 18 years old or older and a dose greater than 6 mg/day will deny at POS with:

**NCPDP rejection code 88 (DUR Reject Error) mapped to
EOB code 529 (Exceeds maximum daily dose)**

After consultation with the prescriber to verify the necessity, the pharmacist may override the denial by submitting the following override at POS:

NCPDP 439-E4 field (Reason for Service Code) HD (High Dose)
NCPDP 440-E5 field (Professional Service Code) MO (Prescriber Consulted)
NCPDP 441-E6 field (Result of Service Code) 1G (Filled with Prescriber Approval)

The pharmacist must document the override codes on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

CARIPRAZINE (VRAYLAR®) THERAPY PACK

Age Limit for cariprazine (Vraylar®) Therapy Pack

For recipients 15 years old or less

All pharmacy claims for any strength of cariprazine (Vraylar®) Therapy Pack will deny for recipients 15 years old or less at POS with:

NCPDP rejection code 60 (Product/Service Not Covered for Patient Age)
mapped to
EOB code 234 (P/F Age Restriction)

There are no override provisions through the POS system using NCPDP service codes.

Quantity Limit for cariprazine (Vraylar®) Therapy Pack

Pharmacy claims for cariprazine (Vraylar®) Therapy Pack will have a quantity limit of 1 package per recipient (not to exceed one package per 18 months). Claims exceeding the quantity limit will reject with:

NCPDP rejection error 76 (Quantity and/or days supply exceeds program maximum) mapped to
EOB Code 457 (Quantity and/or days supply exceeds program maximum)

There are no override provisions through the POS system using NCPDP service codes.

CARIPRAZINE (VRAYLAR®) and CARIPRAZINE (VRAYLAR®) THERAPY PACK

Diagnosis Requirement for cariprazine (Vraylar®) and cariprazine (Vraylar®) Therapy Pack

Pharmacy claims for cariprazine (Vraylar®) and cariprazine (Vraylar®) Therapy Pack require a valid ICD-10-CM diagnosis code submitted at POS. The ICD-10-CM diagnosis code must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system. The chart below contains the valid ICD-10-CM diagnosis codes for cariprazine (Vraylar®).

Diagnosis	ICD-10-CM Diagnosis Code(s)
Schizophrenia or Schizoaffective Disorder	F20.*, F25.*
Major Depressive Disorder, Psychoses in Major Depressive Disorder	F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.9, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9
Delusions, Dementia, Psychoses	F01.*, F02.*, F03.*, F04, F05, F06.0, F06.2, F06.30, F06.31, F06.32, F06.33, F06.34, F06.8, F10.150, F10.151, F10.250, F10.251, F10.26, F10.94, F10.950, F10.951, F10.96, F10.97, F11.121, F11.150, F11.151, F11.221, F11.250, F11.251, F11.921, F11.950, F11.951, F12.121, F12.150, F12.151, F12.221, F12.250, F12.251, F12.921, F12.950, F12.951, F13.121, F13.150, F13.151, F13.221, F13.250, F13.251, F13.27, F13.921, F13.950, F13.951, F13.97, F14.121, F14.150, F14.151, F14.221, F14.250, F14.251, F14.921, F14.950, F14.951, F15.121, F15.150, F15.151, F15.221, F15.250, F15.251, F15.921, F15.950, F15.951, F16.121, F16.150, F16.151, F16.221, F16.250, F16.251, F16.921, F16.950, F16.951, F18.121, F18.150, F18.151, F18.17, F18.221, F18.250, F18.251, F18.27, F18.921, F18.950, F18.951, F18.97, F19.121, F19.150, F19.151, F19.17, F19.221, F19.250, F19.251, F19.27, F19.921, F19.950, F19.951, F19.97, F22, F23, F24, F28, F29, F32.3, F33.3, F44.89
Psychoses in Bipolar Disorder, Psychoses in Other Episodic Mood Disorders	F30.*, F31.*, F32.8, F34.8, F34.9, F39
Aggression or Irritability in Pervasive Developmental Disorder (PDD)	F84.*

Cariprazine (Vraylar®) and cariprazine (Vraylar®) Therapy Pack claims submitted at POS without a valid diagnosis will deny with:

**NCPDP rejection code 39 (Missing or Invalid diagnosis code) mapped to
EOB code 575 (Missing or Invalid diagnosis code)**

Prescribing providers may call Louisiana Medicaid RxPA Operations at the University of Louisiana (ULM) at 1-866-730-4357 for guidance when recipients are established on antipsychotic medications but the ICD-10-CM diagnosis codes submitted are not included in the table of covered diagnoses.

When the diagnosis code written on the prescription is not included in the list of covered diagnoses AND when the pharmacist cannot reach the prescriber OR when the RxPA Center is closed, the pharmacist, using his/her professional judgment, may deem the filling of the antipsychotic prescription to be an "emergency". In these emergency cases, the pharmacist must indicate "Emergency Prescription" on the hardcopy prescription or in the pharmacy's electronic recordkeeping system AND may override the diagnosis code requirement by:

**Placing the ‘alternative’ ICD-10-CM diagnosis code in the NCPDP field 424-DO
(Diagnosis Code) and by placing ‘03’ in NCPDP 418-DI field (Level of Service)**

Compliance associated with program policy will be verified through our Louisiana Medicaid Pharmacy Compliance Audit Program.

Your continued support of the Louisiana Medicaid Program efforts to coordinate care and improve health is greatly appreciated.

JS/MBW/GJS
Attachment

c: Healthy Louisiana Plans
 Melwyn B. Wendt
 Molina

**Louisiana Medicaid
Pharmacy Clinical Pre-Authorization Form**

Fax or Mail this form to:
1-866-797-2329
La Medicaid RxPA Operations
ULM School of Pharmacy
1800 Bienville Drive
Monroe, LA 71201-3765

MEMBER INFORMATION

Revised Date: 2/12/2015

Patient Name: Last Name		First Name		MI	
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female	Height:	Weight:		
Address:		City	State	Zip Code	
Phone #:	Medicaid Recipient ID#: (required)		Plan Policy ID#: (optional)		

PRESCRIBING PRACTITIONER INFORMATION

Practice Name:		Specialty:		NPI # (2):	
Prescribing Practitioner Name:		Medicaid Provider ID #: (required)		NPI # (1):	DEA/License #:
Address:		City	State	Zip Code	
Phone #:	Fax #:	Office Contact:	EPSDT Support Coordinator (Name / Address): (optional)		

MEDICATION INFORMATION

Drug Name:		Dosage Form:		Quantity:	
Strength:	Directions:				
Dispense as Written: <input type="checkbox"/> Yes <input type="checkbox"/> No		Substitutes Permitted: <input type="checkbox"/> Yes <input type="checkbox"/> No		Number of Refills:	
Currently on This Medication: <input type="checkbox"/> Yes <input type="checkbox"/> No		Other Medications Tried to Treat This Condition:		Dates:	
List Other Current Medications: <div style="text-align: right;"><input type="checkbox"/> See attached list</div>					
Reasons for Discontinuation of Tried Therapies:					
Diagnosis/Indication:				ICD Diagnosis Code:	
Rationale and/or Other Information Relevant (<input type="checkbox"/> included lab results) to the Review of This Authorization Request:					
Drug Allergies:					

PHARMACY INFORMATION (Optional)

Pharmacy Name:	Phone #:	Fax #:
----------------	----------	--------

Prescribing Practitioner Signature:

Date:

FAX OR MAIL this form to:
 La Medicaid Rx PA Operations
 ULM School of Pharmacy
 1800 Bienville Drive
 Monroe, LA 71201-3765
 FAX 866-RX PAFAX
 FAX 866-797-2329

State of Louisiana
Department of Health and Hospitals
 Bureau of Health Services Financing
 Louisiana Medicaid Prescription Prior Authorization Program
REQUEST FOR PRESCRIPTION OVERRIDE

Form: Rx PA16
 Issue Date: 3/01/2013
 Revised Date: 2/12/2015
 Voice Phone:
 866-730-4357

Please type or print legibly. Incomplete forms will not be approved.

Date of Request		Number of Fax Pages	
Prescribing Provider Information		Recipient Information	
Name (Last, First)		Name (Last, First)	
LA Medicaid Prescribing Provider Number / NPI		LA Medicaid CCN or Recipient Number	
Provider Specialty		Date of Birth (mm/dd/yy)	
Call-Back Phone Number (include area code)		Recipient Weight (kg)	Recipient Height (ft / in)
FAX Number (Include area code)		Medication Allergies	
Office Contact Name		EPSDT Support Coordinator (Name / Address) <i>(optional)</i>	
Requested Drug Information			
Initiation of Therapy <input type="checkbox"/>		Continuation of Therapy <input type="checkbox"/>	
Drug Name	Drug Strength	Dosage Form	Dosage Interval (sig)
Diagnosis Code [relevant for this request]		Diagnosis Description	Quantity

This request is for:

☐ **For duration of therapy override**

Diagnosis	
Medical Justification	

☐ **For early refill override**

<input type="checkbox"/> Medication lost	<input type="checkbox"/> Physician changed dosage
<input type="checkbox"/> Medication destroyed	<input type="checkbox"/> Medication stolen
<input type="checkbox"/> Patient going out of town for period greater than the day's supply remaining of the previous refill	
Please attach supporting documentation	

☐ **For maximum unit / maximum cost / maximum dose / quantity limit override**

Diagnosis	
Medical Justification	

☐ **For therapeutic duplication**

Diagnosis	
Reason for request	<input type="checkbox"/> Strength / dosage change* <input type="checkbox"/> Titration and concomitant therapy**
Drug name and strength _____ Qty _____	Stop date _____
Drug name and strength _____ Qty _____	Stop date _____
Reason for change	

* Stop date is required for strength / dosage change

** Attach medical justification if both drugs are to be continued (titration / concomitant therapy)

Practitioner Signature: _____

(If a signature stamp is used, then the prescribing practitioner must initial the signature.)

CONFIDENTIAL NOTICE

The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient you are hereby notified that any review, disclosure re-disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.